McLean Asset Management Corp decreased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 9.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,649 shares of the company’s stock after selling 394 shares during the period. McLean Asset Management Corp’s holdings in Johnson & Johnson were worth $566,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of the business. Glassy Mountain Advisors Inc. purchased a new stake in Johnson & Johnson in the 4th quarter valued at $35,000. GW&K Investment Management LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at about $35,000. Dark Forest Capital Management LP boosted its position in shares of Johnson & Johnson by 1,044.4% during the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after acquiring an additional 188 shares during the last quarter. Retirement Financial Solutions LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at about $40,000. Finally, Ruedi Wealth Management Inc. acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at about $42,000. 67.57% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research analysts have recently weighed in on the stock. Credit Suisse Group boosted their price target on shares of Johnson & Johnson from $168.00 to $170.00 in a research report on Friday, May 5th. Atlantic Securities decreased their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 19th. Citigroup started coverage on shares of Johnson & Johnson in a research report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 target price on the stock. StockNews.com started coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They issued a “strong-buy” rating on the stock. Finally, UBS Group started coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 target price on the stock. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $171.57.
Insider Buying and Selling at Johnson & Johnson
Johnson & Johnson Stock Up 1.1 %
JNJ stock opened at $165.62 on Friday. The company’s 50 day moving average price is $160.71 and its 200 day moving average price is $163.69. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35. The firm has a market capitalization of $430.40 billion, a price-to-earnings ratio of 34.65, a PEG ratio of 2.80 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. During the same period in the prior year, the firm earned $2.67 earnings per share. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. On average, equities research analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd were paid a $1.19 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a yield of 2.87%. The ex-dividend date of this dividend was Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is currently 99.58%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free research report on Johnson & Johnson from StockNews.com
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Darden Restaurants: Ring The Register Or Time To Buy?
- United Airlines: Cleared For Takeoff As It Approaches Buy Point?
- KB Home Hits Peak: Pullback Imminent
- Five stocks we like better than Johnson & Johnson
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
